Blinatumomab improves event-free survival in children with high-risk B-cell ALL
A study published in the New England Journal of Medicine indicates that blinatumomab significantly improves event-free survival in children with high-risk B-cell acute lymphoblastic leukemia compared to traditional chemotherapy. The findings suggest a potential shift in the standard of care for pediatric oncology.
Why it matters
This represents a major clinical advancement that could reduce the need for intensive chemotherapy and bone marrow transplants in pediatric cancer patients.
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Blinatumomab is associated with significantly higher event-free survival among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), according to a study published in the Sept. 17 issue of the New England Journal of Medicine .
Dr. Martin Schrappe, of Christian Albrechts University Kiel in Germany, and colleagues randomly assigned children with newly diagnosed high-risk B-cell ALL to receive two cycles of blinatumomab (blinatumomab group) or two cycles of chemotherapy (control group) after consolidation (358 and 351 children, respectively).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in